Invesco Ltd. Clovis Oncology, Inc. Transaction History

Invesco Ltd.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $31,466 - $147,843	-49,947 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $1,006 - $2,210	704 Added 1.43%	49,947 $101,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $4,244 - $7,482	-1,572 Reduced 3.09%	49,243 $134,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $43,616 - $62,309	10,743 Added 26.81%	50,815 $227,000
Q2 2021 Aug 17, 2021	BUY	$5.02 - $7.05 $96,655 - $135,740	19,254 Added 92.49%	40,072 $232,000
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $19,788 - $42,538	4,114 Added 24.63%	20,818 $146,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $68,987 - $107,072	16,704 New	16,704 $80,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $444,030 - $1.3 Million	-117,780 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $308,634 - $1.69 Million	102,878 Added 690.36%	117,780 $1.23 Million
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $2,192 - $8,565	-558 Reduced 3.61%	14,902 $59,000
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $6,802 - $13,630	-531 Reduced 3.32%	15,460 $230,000
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $282,401 - $484,207	15,991 New	15,991 $397,000

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.